SCHEMBL254883

SCHEMBL254883

COCc1ccc(C)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55096 0.85 DAO (0.38)
SCHEMBL16197726 0.83 CHRM2 (0.52)
SCHEMBL16467352 0.82 CHRM2 (0.37)
SCHEMBL18294965 0.79 PDE5A (0.33)
SCHEMBL18659945 0.79
SCHEMBL182997 0.79 CHRM2 (0.44)
SCHEMBL632041 0.77 CHRM2 (0.47)
SCHEMBL22192851 0.77 CHRM2 (0.42)
SCHEMBL19049630 0.76 ALOX5 (0.40)
Ether SCHEMBL17606594 0.76 CHRM2 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
US-20230286997-A1 Compounds for the Treatment of Cancer and Inflammatory Disease SHY Therapeutics LLC 2023-09-14 US disclosed
US-10881666-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2021-01-05 US disclosed
EP-3541792-B1 TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-12-23 EP disclosed
EP-3515912-B1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NAT RECH SCIENT (FR) 2020-10-14 EP disclosed
US-20190192535-A1 COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-06-27 US disclosed
WO-2019038250-A1 BORONIC ACID DERIVATIVES MERCK PATENT GMBH (DE) 2019-02-28 WO disclosed
WO-2018055316-A1 COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-29 WO disclosed
WO-2017142852-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2017-08-24 WO disclosed
US-7985765-B2 Therapeutic substituted pyrroles ALLERGAN, INC. (US) 2011-07-26 US disclosed
WO-2010056717-A1 SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES MERCK SHARP & DOHME CORP. (US) 2010-05-20 WO disclosed
US-7692030-B2 Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer UNIVERSITY OF WASHINGTON (US) 2010-04-06 US disclosed
US-7692030-B2 Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer UNIVERSITY OF WASHINGTON (US) 2010-04-06 US disclosed
US-20100048664-A1 THERAPEUTIC SUBSTITUTED PYRROLES ALLERGAN, INC. (US) 2010-02-25 US disclosed
US-7642265-B2 Benzimidazoles and analogs thereof as antivirals ISIS PHARMACEUTICALS, INC. (US) 2010-01-05 US disclosed
WO-2008118724-A1 INDOLE CARBOXAMIDES AS IKK2 INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-02 WO disclosed
US-20080103192-A1 CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER WASHINGTON, UNIVERSITY OF (US) 2008-05-01 US disclosed
US-20080103192-A1 CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER WASHINGTON, UNIVERSITY OF (US) 2008-05-01 US disclosed
WO-2008046109-A2 CONJUGATES OF ARTEMISININ-RELATED ENDOPEROXIDES AND HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER UNIVERSITY OF WASHINGTON (US) 2008-04-17 WO disclosed